Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07255846 · ClinicalTrials.gov registry record · Phase 1
A Trial of TER-1754 in Patients With Hereditary Hemorrhagic Telangiectasia
A Phase 1 study of Hereditary Hemorrhagic Telangiectasia (HHT), sponsored by Terremoto Biosciences.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 90
- Enrollment target
- 1
- Study location
NCT07255846: Recruiting Phase 1 study of Hereditary Hemorrhagic Telangiectasia (HHT), sponsored by Terremoto Biosciences.
NCT07255846 is a Phase 1 study of Hereditary Hemorrhagic Telangiectasia (HHT) that is actively recruiting participants, run by Terremoto Biosciences. The registered enrollment target is 90 participants, above the 56-participant average among 3 other Hereditary Hemorrhagic Telangiectasia (HHT) trials with a reported enrollment target (61% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07255846, a Phase 1 study of Hereditary Hemorrhagic Telangiectasia (HHT), is actively recruiting participants, sponsored by Terremoto Biosciences.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 90 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a Phase 1a/1b, multicenter study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and clinical activity of TER-1754 (a novel AKT1 inhibitor) in patients with HHT.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG TER-1754
Study Locations (1)
Indiana
- Innovative Hematology, Inc. - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2025-12-15 |
| Est. Completion | 2028-03 |
| Phase | Phase 1 |
What NCT07255846 shows while recruiting
NCT07255846 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 90 participants, a relatively small participant target, above the 56-participant average among 3 other Hereditary Hemorrhagic Telangiectasia (HHT) trials with a reported enrollment target (61% higher).
The record links to 1 condition, with Hereditary Hemorrhagic Telangiectasia (HHT) appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07255846 reports a single indexed study location in Indiana.
Frequently Asked Questions
What is clinical trial NCT07255846 about?
NCT07255846 is a clinical study titled "A Trial of TER-1754 in Patients With Hereditary Hemorrhagic Telangiectasia". This is a Phase 1a/1b, multicenter study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and clinical activity of TER-1754 (a novel AKT1 inhibitor) in patients with HHT.
What is the current status of trial NCT07255846?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 90 participants. The study started on 2025-12-15. Estimated completion is 2028-03.
What conditions does trial NCT07255846 study?
This clinical trial studies the following conditions: Hereditary Hemorrhagic Telangiectasia (HHT).
What interventions are being tested in trial NCT07255846?
The interventions under investigation include: Placebo (DRUG), TER-1754 (DRUG).
Who is sponsoring clinical trial NCT07255846?
This trial is sponsored by Terremoto Biosciences, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07255846 being conducted?
This trial has 1 study location across Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hereditary Hemorrhagic Telangiectasia (HHT)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02521311 · 90 participants · Phase 2
Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)
- NCT02939573 · 90 participants · Phase 2
A Randomized Multicenter Study for Isolated Skin Vasculitis
- NCT03128879 · 90 participants · Phase 2
Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL
- NCT03184038 · 90 participants · NA
Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI